Don Hayden and Lawrence Goldstein join 4M Therapeutics Inc. Board of Directors
FOR IMMEDIATE RELEASE: Wednesday, May 11, 2022
Benjamin C. Williams
4M Therapeutics Inc.
ben@4mtx.net
Don Hayden and Lawrence Goldstein join 4M Therapeutics Inc. Board of Directors
Skillman, NJ: 4M Therapeutics Inc. (4MTx) today announced that Don Hayden and Lawrence Goldstein have joined its Board of Directors.
Don Hayden is an accomplished biopharmaceutical executive and board member, having served earlier in his career at the highest levels in big pharma and thereafter as Chairman or Director of numerous biotechnology companies. During his 25-year career at Bristol-Myers Squibb, Don held a series of key leadership roles including President of Global Pharmaceuticals. Don has served as Board Chairman at a wide range of companies, including REGENXBIO, Amicus Therapeutics, Insmed, Vitae Pharmaceuticals, Gloucester Pharmaceuticals, and WindMIL Therapeutics. He continues to serve as Chairman of Otsuka America Pharmaceuticals Incorporated and Avanir Pharmaceuticals. Don received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.
“I've known Pablo Lapuerta for over 20 years," says Don. "Significant unmet medical need remains in the treatment of neuropsychiatric disorders and neurodegenerative diseases. 4M Therapeutics' unique science offers the opportunity to improve treatment across a range of these disorders and diseases."
“We are honored to have Don join our Board as our Chairman," said Pablo Lapuerta, Founder & CEO at 4MTx. "He brings a wealth of experience and leadership to 4MTx.”
Lawrence SB Goldstein is a Cell Biologist, Geneticist and Neuroscientist recognized for his work on intracellular movements and neurodegenerative disease. Larry was a Full Professor with tenure at Harvard University and then became a Professor (now Emeritus) of Cellular and Molecular Medicine and Neuroscience at UC San Diego. He is also the Scientific Director of the Sanford Consortium for Regenerative Medicine and a co-founder of a public biotechnology, Cytokinetics. Larry has received the Public Service Award from the American Society for Cell Biology and has had a Public Policy Fellowship named for him by the International Society for Stem Cell Research. He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. Larry holds a PhD in Genetics from the University of Washington.
“Using stem cell technology in drug discovery and development is a tremendous advance in biopharma and is particularly critical in neuroscience where both in vitro analyses and animal models have been limited," said Larry. "I am excited to advance our pipeline of small molecules that have the potential to combat disease mechanisms by modulating validated targets.”
“We are honored to have such an accomplished scientist join our Board of Directors,” says Pablo. "His experience with stem-cell based drug discovery, small molecule development, and the mechanisms underpinning neuropsychiatric and neurological disorders are already making an impact at 4MTx.”
About 4M Therapeutics Inc.: 4M Therapeutics Inc. (4MTx) is a startup biotech company based on the principle that the study of human brain cells represents an important advance in neuroscience discovery. 4MTx has developed a pipeline of small molecules by studying their effects on brain cells derived from induced pluripotent stem cells. Our initial focus is bipolar disorder and Alzheimer's disease, conditions where targeted drug discovery can support and improve neuroplasticity and neurogenesis. Join us at www.4mtx.net.